Radiopharm Theranostics Files 6-K

TL;DR

Radiopharm Theranostics filed a routine 6-K, no major news yet.

AI Summary

Radiopharm Theranostics Limited filed a Form 6-K on December 19, 2024, reporting information for the month of December 2024. The company is a foreign private issuer and is providing updates as required by the SEC. The filing does not contain specific financial figures or significant operational announcements within the provided text.

Why It Matters

This filing indicates ongoing reporting compliance by Radiopharm Theranostics Limited with the U.S. Securities and Exchange Commission, which is standard for foreign private issuers.

Risk Assessment

Risk Level: low — This filing is a standard report for a foreign private issuer and does not contain information that inherently increases risk.

Key Players & Entities

• Radiopharm Theranostics Limited (company) — Registrant
• 001-41621 (company) — SEC File Number
• December 2024 (date) — Reporting Period
• 20241219 (date) — Filing Date

FAQ

Filing Documents

• ea0225315-6k_radio.htm (6-K) — 12KB
• ea022531501ex99-1_radio.htm (EX-99.1) — 39KB
• ex99-1_001.jpg (GRAPHIC) — 2KB
• 0001213900-24-110309.txt ( ) — 55KB

From the Filing

OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December 2024 Commission File Number: 001-41621 RADIOPHARM THERANOSTICS LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes No If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- RADIOPHARM THERANOSTICS LIMITED EXPLANATORY NOTE Radiopharm Theranostics Limited (the “Company”) published one announcement (the “Public Notice”) to the Australian Securities Exchange on December 19, 2024 titled: - “Application for quotation of securities – RAD” A copy of the Public Notice are attached as an exhibit to this report on Form 6-K. This report on Form 6-K (including the exhibit hereto) shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing. 1 EXHIBITS Exhibit Number Description 99.1 Application for quotation of securities – RAD 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. RADIOPHARM THERANOSTICS LIMITED Date: December 19, 2024 By: /s/ Phillip Hains Phillip Hains Company Secretary 3

View Full Filing

View this 6-K filing on SEC EDGAR